Which has stronger valuation and earnings, CELC or SVRA?

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is CELC or SVRA more profitable?

Savara's return on equity of -90.28% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Savara N/A -90.28% -68.95%

Does the media prefer CELC or SVRA?

In the previous week, Celcuity had 2 more articles in the media than Savara. MarketBeat recorded 7 mentions for Celcuity and 5 mentions for Savara. Celcuity's average media sentiment score of 0.91 beat Savara's score of 0.83 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SVRA more profitable?

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Savara N/A -90.28% -68.95%

Does the media refer more to RLAY or SVRA?

In the previous week, Savara had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 5 mentions for Savara and 3 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.88 beat Savara's score of 0.83 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, TLX or SVRA?

Telix Pharmaceuticals has higher revenue and earnings than Savara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $890.79M 4.19 -$7.12M N/A N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is TLX or SVRA more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Savara N/A -90.28% -68.95%

Does the media refer more to TLX or SVRA?

In the previous week, Telix Pharmaceuticals had 9 more articles in the media than Savara. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat Telix Pharmaceuticals' score of 0.45 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or SVRA more profitable?

Tango Therapeutics' return on equity of -25.75% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Savara N/A -90.28% -68.95%

Does the media refer more to TNGX or SVRA?

In the previous week, Tango Therapeutics had 5 more articles in the media than Savara. MarketBeat recorded 10 mentions for Tango Therapeutics and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat Tango Therapeutics' score of 0.66 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SVRA or ABCL?

In the previous week, AbCellera Biologics had 11 more articles in the media than Savara. MarketBeat recorded 16 mentions for AbCellera Biologics and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat AbCellera Biologics' score of 0.24 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Savara (SVRA) Competitors

$5.14 +0.06 (+1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$5.30 +0.16 (+3.15%)

As of 05:24 PM Eastern

Compare

SVRA vs. CELC, RLAY, TLX, TNGX, and ABCL

Should you buy Savara stock or one of its competitors? Savara's main competitors and comparable companies include Celcuity (CELC), Relay Therapeutics (RLAY), Telix Pharmaceuticals (TLX), Tango Therapeutics (TNGX), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Savara compare to Celcuity?

Celcuity (NASDAQ:CELC) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

In the previous week, Celcuity had 2 more articles in the media than Savara. MarketBeat recorded 7 mentions for Celcuity and 5 mentions for Savara. Celcuity's average media sentiment score of 0.91 beat Savara's score of 0.83 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Celcuity has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 13.3% of Celcuity shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Celcuity presently has a consensus target price of $154.25, suggesting a potential upside of 93.98%. Savara has a consensus target price of $10.00, suggesting a potential upside of 94.55%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara's return on equity of -90.28% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Savara	N/A	-90.28%	-68.95%

Summary

Savara beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Savara compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Savara had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 5 mentions for Savara and 3 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.88 beat Savara's score of 0.83 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Savara has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35M	382.18	-$276.48M	-$1.57	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Savara	N/A	-90.28%	-68.95%

Relay Therapeutics presently has a consensus target price of $25.92, indicating a potential upside of 43.58%. Savara has a consensus target price of $10.00, indicating a potential upside of 94.55%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Savara on 9 of the 15 factors compared between the two stocks.

How does Savara compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Telix Pharmaceuticals had 9 more articles in the media than Savara. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat Telix Pharmaceuticals' score of 0.45 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Savara	N/A	-90.28%	-68.95%

Telix Pharmaceuticals presently has a consensus target price of $20.50, indicating a potential upside of 86.87%. Savara has a consensus target price of $10.00, indicating a potential upside of 94.55%. Given Savara's higher possible upside, analysts clearly believe Savara is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than Savara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$890.79M	4.19	-$7.12M	N/A	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Summary

Telix Pharmaceuticals and Savara tied by winning 6 of the 12 factors compared between the two stocks.

How does Savara compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Tango Therapeutics had 5 more articles in the media than Savara. MarketBeat recorded 10 mentions for Tango Therapeutics and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat Tango Therapeutics' score of 0.66 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has higher revenue and earnings than Savara. Tango Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	78.28	-$101.59M	-$0.85	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Tango Therapeutics presently has a consensus target price of $43.46, suggesting a potential upside of 73.96%. Savara has a consensus target price of $10.00, suggesting a potential upside of 94.55%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics' return on equity of -25.75% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Savara	N/A	-90.28%	-68.95%

Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

Tango Therapeutics beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to AbCellera Biologics?

Savara (NASDAQ:SVRA) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

87.9% of Savara shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Savara has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
AbCellera Biologics	$66.17M	67.56	-$146.41M	-$0.54	N/A

Savara presently has a consensus price target of $10.00, suggesting a potential upside of 94.55%. AbCellera Biologics has a consensus price target of $13.38, suggesting a potential downside of 8.26%. Given Savara's stronger consensus rating and higher possible upside, equities research analysts clearly believe Savara is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Savara has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

In the previous week, AbCellera Biologics had 11 more articles in the media than Savara. MarketBeat recorded 16 mentions for AbCellera Biologics and 5 mentions for Savara. Savara's average media sentiment score of 0.83 beat AbCellera Biologics' score of 0.24 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Savara beats AbCellera Biologics on 8 of the 15 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.06B	$3.93B	$7.21B	$13.07B
Dividend Yield	N/A	3.63%	2.52%	14.18%
P/E Ratio	-8.86	13.43	274.05	25.71
Price / Sales	N/A	1,446.64	668.48	97.73
Price / Cash	N/A	121.91	80.06	52.35
Price / Book	5.14	15.13	10.34	6.29
Net Income	-$118.84M	-$22.71M	$3.50B	$360.55M
7 Day Performance	2.80%	-1.92%	-1.69%	-1.84%
1 Month Performance	-2.28%	-8.34%	-4.60%	-4.35%
1 Year Performance	43.98%	26.48%	12.42%	3.58%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.8548 of 5 stars	$5.14 +1.2%	$10.00 +94.6%	+44.3%	$1.06B	N/A	N/A	70	High Trading Volume
CELC Celcuity	3.173 of 5 stars	$84.01 +0.0%	$154.75 +84.2%	+48.6%	$4.12B	N/A	N/A	155	News Coverage Analyst Forecast Gap Up
RLAY Relay Therapeutics	2.5359 of 5 stars	$18.77 +3.2%	$25.92 +38.1%	+253.8%	$4.11B	$15.35M	N/A	192
TLX Telix Pharmaceuticals	4.618 of 5 stars	$12.00 +6.1%	$20.40 +70.1%	+14.7%	$4.07B	$803.79M	N/A	1,184	Gap Up
TNGX Tango Therapeutics	2.5451 of 5 stars	$23.45 +5.0%	$43.46 +85.4%	+189.3%	$3.96B	$62.38M	N/A	137

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, TLX, TNGX, and ABCL

How does Savara compare to Celcuity?

Summary

How does Savara compare to Relay Therapeutics?

Summary

How does Savara compare to Telix Pharmaceuticals?

Summary

How does Savara compare to Tango Therapeutics?

Summary

How does Savara compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, TLX, TNGX, and ABCL

How does Savara compare to Celcuity?

Does the media prefer CELC or SVRA?

Which has stronger valuation and earnings, CELC or SVRA?

Which has more risk & volatility, CELC or SVRA?

Do institutionals & insiders have more ownership in CELC or SVRA?

Do analysts rate CELC or SVRA?

Is CELC or SVRA more profitable?

Summary

How does Savara compare to Relay Therapeutics?

Does the media refer more to RLAY or SVRA?

Which has more volatility & risk, RLAY or SVRA?

Which has preferable earnings and valuation, RLAY or SVRA?

Is RLAY or SVRA more profitable?

Do analysts rate RLAY or SVRA?

Do institutionals & insiders believe in RLAY or SVRA?

Summary

How does Savara compare to Telix Pharmaceuticals?

Does the media refer more to TLX or SVRA?

Is TLX or SVRA more profitable?

Do analysts prefer TLX or SVRA?

Do institutionals and insiders believe in TLX or SVRA?

Which has higher earnings & valuation, TLX or SVRA?

Which has more volatility & risk, TLX or SVRA?

Summary

How does Savara compare to Tango Therapeutics?

Does the media refer more to TNGX or SVRA?

Which has preferable valuation & earnings, TNGX or SVRA?

Do analysts recommend TNGX or SVRA?

Do insiders & institutionals have more ownership in TNGX or SVRA?

Is TNGX or SVRA more profitable?

Which has more volatility & risk, TNGX or SVRA?

Summary

How does Savara compare to AbCellera Biologics?

Do insiders & institutionals hold more shares of SVRA or ABCL?

Which has preferable valuation & earnings, SVRA or ABCL?

Do analysts prefer SVRA or ABCL?

Is SVRA or ABCL more profitable?

Which has more risk & volatility, SVRA or ABCL?

Does the media prefer SVRA or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools